SEE-DRUG

ESTABLISHMENT OF A CENTRE OF EXCELLENCE FOR STRUCTURE-BASED DRUG TARGET CHARACTERIZATION: STRENGTHENING THE RESEARCH CAPACITY OF SOUTH-EASTERN EUROPE

Coordinatore	UNIVERSITY OF PATRAS    more  Organization address address: UNIVERSITY CAMPUS RIO PATRAS city: RIO PATRAS postcode: 26500 contact info Titolo: Prof. Nome: Georgios A. Cognome: Spyroulias Email: send email Telefono: +30 2610 969950 Fax: +30 2610 969950
Nazionalità Coordinatore	Greece [EL]
Totale costo	3˙586˙420 €
EC contributo	3˙199˙527 €
Programma	FP7-REGPOT Specific Programme "Capacities": Research potential of Convergence Regions
Code Call	FP7-REGPOT-2011-1
Funding Scheme	CSA-SA
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2015-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF PATRAS  Organization address address: UNIVERSITY CAMPUS RIO PATRAS city: RIO PATRAS postcode: 26500 contact info Titolo: Prof. Nome: Georgios A. Cognome: Spyroulias Email: send email Telefono: +30 2610 969950 Fax: +30 2610 969950	EL (RIO PATRAS)	coordinator	3˙199˙527.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'SEE-DRUG’s Major Aim is to strengthen and broaden the scientific reach and socio-economic impact of the University of Patras (UPAT) through the creation of a Regional Centre of Excellence for Structural Biology that emphasizes the characterization and development of bioactive molecules with therapeutic potential. SEE-DRUG takes advantage of UPAT’s pivotal strength and growth potential of Structural Biology and combines it with high-quality, multidisciplinary scientific expertise in Chemistry, Pharmacology, Biology & Bioinformatics. The SEE-DRUG project will enable: (a) the Protein Production group to efficiently produce and characterize protein drug-targets for structural analysis and drug development efforts, (b) the Structural Biology group to perform high-resolution structure determination, through time- and cost-effective NMR-based, cutting-edge techniques, and (c) the Pharmacology group to characterize lead therapeutic molecules in a comprehensive array of in vitro, ex vivo and in vivo systems. The long-term benefits of SEE-DRUG implementation will manifest on 3 levels: (a) the pooling of scientific expertise & the upgrading of infrastructure within UPAT, (b) the optimal integration of UPAT’s Structural Biology in ERA through the establishment of long-lasting partnerships, (c) the creation of a solid scientific platform that will become a pole for therapeutic biomolecule-oriented Structural Biology in Greece and in SouthEastern EU, and (d) the exchange of expertise (via twinning actions with 8 EU partnering organizations) and the building of networks with other scientists and technology end-users at a regional or local level, including the bio-pharmaceutical industry. Last, but not least, such a state-of-the-art Centre will create a number of positions for highly skilled scientists and thus enhance scientific and economic growth both at a local and at a regional level, which will hopefully be sustained for years to come.'